Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
STOP-LTR
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
2 other identifiers
interventional
600
19 countries
308
Brief Summary
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for phase_3
Started Feb 2025
Typical duration for phase_3
308 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 26, 2025
CompletedStudy Start
First participant enrolled
February 28, 2025
CompletedFirst Posted
Study publicly available on registry
March 3, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2028
ExpectedStudy Completion
Last participant's last visit for all outcomes
February 28, 2028
May 4, 2026
April 1, 2026
3 years
February 26, 2025
April 30, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Proportion of participants with Treatment-Emergent Adverse Events (TEAEs)
Adverse events either reported for the first time in this Protocol or any AE ongoing and defined as treatment-emergent from the parent Protocol.
Up to approximately 3 years
Secondary Outcomes (1)
Proportion of participants with a total ANdT count of 0, 1, or 2 at each visit
Up to approximately 3 years
Study Arms (1)
povorcitinib
EXPERIMENTALParticipants will receive povorcitinib treatment with the same schedule and dose options as the study in which they originally enrolled.
Interventions
Eligibility Criteria
You may qualify if:
- Ability to comprehend and willingness to sign a written ICF for the study.
- Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
- Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
- Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
- Willingness to avoid pregnancy or fathering children as defined in the protocol.
- Willingness and ability to comply with the study Protocol and procedures.
You may not qualify if:
- Had been permanently discontinued from study treatment during the parent study.
- Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
- Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
- Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
- Live, attenuated vaccine.
- Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
- Women who are pregnant (or who are considering pregnancy) or breastfeeding.
- Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.
- Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study.
- Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (318)
Investigative Site US086
Birmingham, Alabama, 35244, United States
Investigative Site US098
Montgomery, Alabama, 36117, United States
Investigative Site US004
Phoenix, Arizona, 85006, United States
Investigative Site US047
Scottsdale, Arizona, 85255, United States
Investigative Site US124
Scottsdale, Arizona, 85255, United States
Investigative Site US115
Tucson, Arizona, 85718, United States
Investigative Site US113
Fayetteville, Arkansas, 72703, United States
Investigative Site US009
Rogers, Arkansas, 72758, United States
Investigative Site US076
Fountain Valley, California, 92708-3701, United States
Investigative Site US077
Fremont, California, 94538, United States
Investigative Site US071
Huntington Beach, California, 92647, United States
Investigative Site US020
Laguna Niguel, California, 92677, United States
Investigative Site US036
Los Angeles, California, 90033, United States
Investigative Site US067
Los Angeles, California, 90045, United States
Investigative Site US060
Northridge, California, 91325, United States
Investigative Site US037
Oakland, California, 94611, United States
Investigative Site US089
Santa Monica, California, 90404, United States
Investigative Site US080
Sherman Oaks, California, 91403, United States
Investigative Site US129
Aventura, Florida, 33180, United States
Investigative Site US116
Boca Raton, Florida, 33428, United States
Investigative Site US002
Boca Raton, Florida, 33486, United States
Investigative Site US062
Coral Gables, Florida, 33134, United States
Investigative Site US084
Coral Gables, Florida, 33146, United States
Investigative Site US017
Hialeah, Florida, 33012, United States
Investigative Site US019
Hollywood, Florida, 33021-6746, United States
Investigative Site US090
Hollywood, Florida, 33024, United States
Investigative Site US044
Margate, Florida, 33063, United States
Investigative Site US015
Miami, Florida, 33136, United States
Investigative Site US059
Miami, Florida, 33173, United States
Investigative Site US072
Miami Lakes, Florida, 33014, United States
Investigative Site US079
Miami Lakes, Florida, 33014, United States
Investigative Site US023
North Miami Beach, Florida, 33162, United States
Investigative Site US029
Ocala, Florida, 34470, United States
Investigative Site US133
Tampa, Florida, 33607, United States
Investigative Site US035
Tampa, Florida, 33609, United States
Investigative Site US005
Tampa, Florida, 33613, United States
Investigative Site US001
Tampa, Florida, 33615, United States
Investigative Site US066
West Palm Beach, Florida, 33401, United States
Investigative Site US070
West Palm Beach, Florida, 33401, United States
Investigative Site US051
Marietta, Georgia, 30060-1047, United States
Investigative Site US103
Sandy Springs, Georgia, 30328, United States
Investigative Site US100
Stonecrest, Georgia, 30038, United States
Investigative Site US125
Chicago, Illinois, 60602, United States
Investigative Site US093
Chicago, Illinois, 60657, United States
Investigative Site US049
Skokie, Illinois, 60077, United States
Investigative Site US039
West Dundee, Illinois, 60118, United States
Investigative Site US108
Indianapolis, Indiana, 46202, United States
Investigative Site US008
Indianapolis, Indiana, 46250, United States
Investigative Site US064
West Lafayette, Indiana, 47906, United States
Investigative Site US056
Bowling Green, Kentucky, 42104, United States
Investigative Site US012
Baton Rouge, Louisiana, 70809, United States
Investigative Site US057
New Orleans, Louisiana, 70115, United States
Investigative Site US111
Baltimore, Maryland, 21201, United States
Investigative Site US038
Baltimore, Maryland, 21287-0876, United States
Investigative Site US099
Glenn Dale, Maryland, 20769, United States
Investigative Site US053
Marriottsville, Maryland, 21104, United States
Investigative Site US101
Rockville, Maryland, 20850, United States
Investigative Site US127
Rockville, Maryland, 20850, United States
Investigative Site US030
Boston, Massachusetts, 02215, United States
Investigative Site US048
Brighton, Massachusetts, 02135, United States
Investigative Site US061
Ann Arbor, Michigan, 48103, United States
Investigative Site US114
Auburn Hills, Michigan, 48326, United States
Investigative Site US120
Detroit, Michigan, 48202, United States
Investigative Site US091
Troy, Michigan, 48084, United States
Investigative Site US128
Troy, Michigan, 48084, United States
Investigative Site US042
Waterford, Michigan, 48328, United States
Investigative Site US011
Minneapolis, Minnesota, 55455, United States
Investigative Site US088
Saint Joseph, Missouri, 64506, United States
Investigative Site US016
St Louis, Missouri, 63110, United States
Investigative Site US007
Portsmouth, New Hampshire, 03801, United States
Investigative Site US121
Hackensack, New Jersey, 07601, United States
Investigative Site US118
Albuquerque, New Mexico, 87131, United States
Investigative Site US082
East Syracuse, New York, 13057, United States
Investigative Site US123
East Syracuse, New York, 13057, United States
Investigative Site US040
Kew Gardens, New York, 11415, United States
Investigative Site US034
New York, New York, 10028-3135, United States
Investigative Site US081
New York, New York, 10075, United States
Investigative Site US065
New York, New York, 10128, United States
Investigative Site US075
New York, New York, 10956, United States
Investigative Site US050
Rochester, New York, 14642, United States
Investigative Site US131
Stony Brook, New York, 11790, United States
Investigative Site US031
Chapel Hill, North Carolina, 27516, United States
Investigative Site US028
Bexley, Ohio, 43209, United States
Investigative Site US055
Boardman, Ohio, 44512, United States
Investigative Site US025
Cincinnati, Ohio, 45219, United States
Investigative Site US073
Columbus, Ohio, 43215, United States
Investigative Site US033
Columbus, Ohio, 43230-5317, United States
Investigative Site US130
Dayton, Ohio, 45324, United States
Investigative Site US117
Dublin, Ohio, 43016, United States
Investigative Site US085
Oklahoma City, Oklahoma, 73170, United States
Investigative Site US074
Philadelphia, Pennsylvania, 19103, United States
Investigative Site US069
Plymouth Meeting, Pennsylvania, 19462, United States
Investigative Site US119
Yardley, Pennsylvania, 19067, United States
Investigative Site US021
Bellaire, Texas, 77401, United States
Investigative Site US078
Dallas, Texas, 75230, United States
Investigative Site US010
Dallas, Texas, 75246, United States
Investigative Site US054
Pflugerville, Texas, 78660, United States
Investigative Site US083
San Antonio, Texas, 78218, United States
Investigative Site US126
Sugar Land, Texas, 77479, United States
Investigative Site US068
Webster, Texas, 77598, United States
Investigative Site US122
Murray, Utah, 84107, United States
Investigative Site US063
South Jordan, Utah, 84095, United States
Investigative Site US027
Norfolk, Virginia, 23502, United States
Investigative Site US094
Richmond, Virginia, 23226, United States
Investigative Site US132
Mill Creek, Washington, 98012, United States
Investigative Site US092
Seattle, Washington, 98168, United States
Investigative Site US003
Spokane, Washington, 99202, United States
Investigative Site AR005
Buenos Aires, 01018, Argentina
Investigative Site AR002
Buenos Aires, C1060ABN, Argentina
Investigative Site AR006
Buenos Aires, C1425BEN, Argentina
Investigative Site AR004
Mar del Plata, B7600FYK, Argentina
Investigative Site AR003
Rosario, S2000, Argentina
Investigative Site AR001
San Miguel de Tucumán, T4000AXL, Argentina
Investigative Site AU001
Charleston, New South Wales, 02290, Australia
Investigative Site AU003
Kogarah, New South Wales, 02217, Australia
Investigative Site AU005
Liverpool, New South Wales, 02170, Australia
Investigative Site AU010
Sydney, New South Wales, 02010, Australia
Investigative Site AU007
Wolloongabba, Queensland, 04102, Australia
Investigative Site AU004
Carlton, Victoria, 03053, Australia
Investigative Site AU002
Melbourne, Victoria, 03002, Australia
Investigative Site AU011
Melbourne, Victoria, 03004, Australia
Investigative Site AU008
Fremantle, 06160, Australia
Investigative Site AU009
Westmead, 02145, Australia
Investigative Site AT002
Graz, 08036, Austria
Investigative Site AT004
Innsbruck, 06020, Austria
Investigative Site AT003
Vienna, 01130, Austria
Investigative Site BE007
Bruges, 08000, Belgium
Investigative Site BE002
Brussels, 01070, Belgium
Investigative Site BE001
Ghent, 09000, Belgium
Investigative Site BE003
Liège, 04000, Belgium
Investigative Site BE006
Loverval, 06280, Belgium
Investigative Site BE005
Woluwe-Saint-Lambert, 01200, Belgium
Investigative Site BG008
Dupnitsa, 02600, Bulgaria
Investigative Site BG010
Lovech, 05500, Bulgaria
Investigative Site BG012
Pleven, 05800, Bulgaria
Investigative Site BG013
Plovdiv, 04002, Bulgaria
Investigative Site BG007
Sevlievo, 05400, Bulgaria
Investigative Site BG009
Sofia, 01202, Bulgaria
Investigative Site BG002
Sofia, 01407, Bulgaria
Investigative Site BG006
Sofia, 01431, Bulgaria
Investigative Site BG011
Sofia, 01431, Bulgaria
Investigative Site BG003
Sofia, 01463, Bulgaria
Investigative Site BG001
Sofia, 01510, Bulgaria
Investigative Site BG014
Sofia, 01528, Bulgaria
Investigative Site BG004
Stara Zagora, 06003, Bulgaria
Investigative Site CA023
Calgary, Alberta, T2J 7E1, Canada
Investigative Site CA008
Calgary, Alberta, T3E 0B2, Canada
Investigative Site CA005
Edmonton, Alberta, T6G 1C3, Canada
Investigative Site CA028
Edmonton, Alberta, T6W 4V4, Canada
Investigative Site CA027
Edmonton, Alberta, T6X 0N9, Canada
Investigative Site CA031
Sherwood Park, Alberta, T8H 0P1, Canada
Investigative Site CA013
Surrey, British Columbia, V3V 0C6, Canada
Investigative Site CA024
Vancouver, British Columbia, V5Z 4E8, Canada
Investigative Site CA003
Winnipeg, Manitoba, R3M 3Z4, Canada
Investigative Site CA004
Barrie, Ontario, L4M 7G1, Canada
Investigative Site CA030
Cobourg, Ontario, K9A 0Z4, Canada
Investigative Site CA025
London, Ontario, N6A 2C2, Canada
Investigative Site CA002
London, Ontario, N6H 5L5, Canada
Investigative Site CA022
Markham, Ontario, L3P 1X3, Canada
Investigative Site CA016
Mississauga, Ontario, L4Y 4C5, Canada
Investigative Site CA001
Peterborough, Ontario, K9J 5K2, Canada
Investigative Site CA010
Richmond Hill, Ontario, L4C 9M7, Canada
Investigative Site CA017
Toronto, Ontario, M2N 3A6, Canada
Investigative Site CA018
Toronto, Ontario, M3H 5Y8, Canada
Investigative Site CA021
Toronto, Ontario, M4W 2N4, Canada
Investigative Site CA019
Waterloo, Ontario, N2J 1C4, Canada
Investigative Site CA020
Québec, Quebec, G1V4X7, Canada
Investigative Site CA026
Québec, Quebec, G1W 4R4, Canada
Investigative Site CA009
Saint-Jérôme, Quebec, J7Z 7E2, Canada
Investigative Site CA029
Verdun, Quebec, H4G 3E7, Canada
Investigative Site CA015
Saskatoon, Saskatchewan, S7K 2C1, Canada
Investigative Site CL002
LAS Condes Santiago, 7580206, Chile
Investigative Site CL003
Santiago, 8420383, Chile
Investigative Site CL001
Valdivia, 5090000, Chile
Investigative Site CZ002
Ostrava-poruba, 708 52, Czechia
Investigative Site CZ004
Prague, 100 00, Czechia
Investigative Site CZ003
Prague, 110 00, Czechia
Investigative Site CZ001
Prague, 150 06, Czechia
Investigative Site FR014
Antony, 92160, France
Investigative Site FR006
Bordeaux, 33000, France
Investigative Site FR004
Brest, 29609, France
Investigative Site FR015
Créteil, 94000, France
Investigative Site FR009
Lyon, 69003, France
Investigative Site FR012
Marseille, 13005, France
Investigative Site FR011
Nantes, 44093, France
Investigative Site FR008
Nice, 06200, France
Investigative Site FR010
Paris, 75010, France
Investigative Site FR005
Reims, 51100, France
Investigative Site FR018
Romans-sur-Isère, 26102, France
Investigative Site FR007
Rouen, 76031, France
Investigative Site FR003
Saint-Priest-en-Jarez, 42270, France
Investigative Site FR001
Toulouse, 31059, France
Investigative Site DE036
Aachen, 52074, Germany
Investigative Site DE025
Bad Bentheim, 48455, Germany
Investigative Site DE005
Berlin, 10117, Germany
Investigative Site DE026
Berlin, 10247, Germany
Investigative Site DE006
Bochum, 44791, Germany
Investigative Site DE037
Bonn, 53105, Germany
Investigative Site DE024
Buxtehude, 21614, Germany
Investigative Site DE023
Chemnitz, 09117, Germany
Investigative Site DE013
Darmstadt, 64283, Germany
Investigative Site DE019
Darmstadt, 64283, Germany
Investigative Site DE027
Dortmund, 44137, Germany
Investigative Site DE012
Dresden, 01307, Germany
Investigative Site DE014
Düsseldorf, 40225, Germany
Investigative Site DE009
Erlangen, 91054, Germany
Investigative Site DE011
Frankfurt am Main, 60590, Germany
Investigative Site DE010
Göttingen, 37075, Germany
Investigative Site DE032
Halle, 06120, Germany
Investigative Site DE001
Hamburg, 20246, Germany
Investigative Site DE002
Hanover, 30159, Germany
Investigative Site DE017
Heidelberg, 69115, Germany
Investigative Site DE003
Kiel, 24105, Germany
Investigative Site DE033
Leipzig, 04103, Germany
Investigative Site DE034
Lübeck, 23538, Germany
Investigative Site DE029
Magdeburg, 39104, Germany
Investigative Site DE015
Mainz, 55128, Germany
Investigative Site DE035
Mainz, 55131, Germany
Investigative Site DE038
Marburg, 35043, Germany
Investigative Site DE008
Merzig, 66663, Germany
Investigative Site DE030
München, 80802, Germany
Investigative Site DE028
Oldenburg, 26133, Germany
Investigative Site DE031
Tübingen, 72076, Germany
Investigative Site DE018
Witten, 58453, Germany
Investigative Site GR001
Athens, 12462, Greece
Investigative Site GR002
Athens, 16121, Greece
Investigative Site GR003
Thessaloniki, 56429, Greece
Investigative Site HU001
Debrecen, 04032, Hungary
Investigative Site HU002
Szombathely, Hungary
Investigative Site IT012
Bari, 70124, Italy
Investigative Site IT009
Brescia, 25123, Italy
Investigative Site IT001
Catania, 95123, Italy
Investigative Site IT007
Chieti, 66013, Italy
Investigative Site IT014
Florence, 50125, Italy
Investigative Site IT010
L’Aquila, 67100, Italy
Investigative Site IT005
Milan, 20122, Italy
Investigative Site IT008
Naples, 80131, Italy
Investigative Site IT013
Perugia, 06129, Italy
Investigative Site IT006
Pisa, 56126, Italy
Investigative Site IT002
Rome, 00168, Italy
Investigative Site IT003
Rozzano, 20089, Italy
Investigative Site IT004
Torrette DI Ancona, 60020, Italy
Investigative Site NL005
Amsterdam, 1105 AZ, Netherlands
Investigative Site NL007
Amsterdam, 1105 AZ, Netherlands
Investigative Site NL006
Bergen op Zoom, 4624 VT, Netherlands
Investigative Site NL003
Groningen, 9713 GZ, Netherlands
Investigative Site NL001
Rotterdam, 3015 GD, Netherlands
Investigative Site NL004
Veldhoven, 5504 DB, Netherlands
Investigative Site PL013
Cracov, 30-348, Poland
Investigative Site PL009
Gdansk, 80-280, Poland
Investigative Site PL029
Grodzisk Mazowiecki, Poland
Investigative Site PL011
Katowice, 40-568, Poland
Investigative Site PL025
Katowice, 40-600, Poland
Investigative Site PL021
Lodz, 90-436, Poland
Investigative Site PL031
Lublin, 20-406, Poland
Investigative Site PL002
Lublin, 20-573, Poland
Investigative Site PL020
Osielsko, 86-031, Poland
Investigative Site PL006
Ostrowiec Świętokrzyski, 27-400, Poland
Investigative Site PL016
Poznan, 61731, Poland
Investigative Site PL003
Rzeszów, 35-055, Poland
Investigative Site PL043
Skierniewice, 96-100, Poland
Investigative Site PL028
Szczecin, 70-332, Poland
Investigative Site PL010
Tarnów, 33-100, Poland
Investigative Site PL030
Torun, 87-100, Poland
Investigative Site PL046
Warsaw, 00-124, Poland
Investigative Site PL017
Warsaw, 01-142, Poland
Investigative Site PL026
Warsaw, 01-817, Poland
Investigative Site PL007
Warsaw, 02-507, Poland
Investigative Site PL014
Warsaw, 02-625, Poland
Investigative Site PL012
Warsaw, 02-661, Poland
Investigative Site PL004
Warsaw, 02-692, Poland
Investigative Site PL027
Warsaw, 02-953, Poland
Investigative Site PL024
Wrocaw, 03-291, Poland
Investigative Site PL018
Wroclaw, 50-450, Poland
Investigative Site PL001
Wroclaw, 50-566, Poland
Investigative Site PL005
Wroclaw, 51-503, Poland
Investigative Site PL015
Wroclaw, 52-416, Poland
Investigative Site PL008
Wroclaw, 54144, Poland
Investigative Site PL022
Wroclaw, 54144, Poland
Investigative Site KR006
Ansan-si, 15355, South Korea
Investigative Site KR008
Bucheon-si, 14584, South Korea
Investigative Site KR007
Busan, 49241, South Korea
Investigative Site KR003
Incheon, 21431, South Korea
Investigative Site KR004
Jeonju, 54907, South Korea
Investigative Site KR002
Seoul, 03080, South Korea
Investigative Site KR005
Seoul, 05030, South Korea
Investigative Site KR001
Yangsan, 50612, South Korea
Investigative Site ES025
Alicante, 03010, Spain
Investigative Site ES001
Badalona, 08916, Spain
Investigative Site ES024
Badalona, 08916, Spain
Investigative Site ES010
Barcelona, 08003, Spain
Investigative Site ES017
Barcelona, 08026, Spain
Investigative Site ES015
Córdoba, 14004, Spain
Investigative Site ES003
Granada, 18014, Spain
Investigative Site ES013
Granada, 18016, Spain
Investigative Site ES006
Las Palmas de Gran Canaria, 35010, Spain
Investigative Site ES014
Madrid, 28034, Spain
Investigative Site ES008
Madrid, 28040, Spain
Investigative Site ES011
Madrid, 28041, Spain
Investigative Site ES012
Madrid, 28046, Spain
Investigative Site ES004
Manises, 46940, Spain
Investigative Site ES022
Pamplona, 31008, Spain
Investigative Site ES002
Santiago de Compostela, 15706, Spain
Investigative Site ES018
Valencia, 46026, Spain
Investigative Site CH003
Bern, 03010, Switzerland
Investigative Site CH001
Buochs, 06374, Switzerland
Investigative Site CH002
Zurich, 08091, Switzerland
Investigative Site GB003
Birmingham, B15 2GW, United Kingdom
Investigative Site GB001
Dudley, DY1 2HQ, United Kingdom
Investigative Site GB011
Ipswich, IP4 5PD, United Kingdom
Investigative Site GB009
Leicester, LE1 5WW, United Kingdom
Investigative Site GB013
Liverpool, L14 3LB, United Kingdom
Investigative Site GB012
London, E11 1NR, United Kingdom
Investigative Site GB014
London, SE1 9RT, United Kingdom
Investigative Site GB006
Poole, BH15 2JB, United Kingdom
Investigative Site GB007
Redhill, RH1 5RH, United Kingdom
Investigative Site GB004
Salford, M6 8HD, United Kingdom
Investigative Site GB008
Wolverhampton, WV10 0QP, United Kingdom
Related Links
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Incyte Medical Monitor
Incyte Corporation
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 26, 2025
First Posted
March 3, 2025
Study Start
February 28, 2025
Primary Completion (Estimated)
February 28, 2028
Study Completion (Estimated)
February 28, 2028
Last Updated
May 4, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP
- Time Frame
- Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
- Access Criteria
- Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency